首页> 外文期刊>Drug delivery and translational research >Collagen biomaterial for the treatment of myocardial infarction: an update on cardiac tissue engineering and myocardial regeneration
【24h】

Collagen biomaterial for the treatment of myocardial infarction: an update on cardiac tissue engineering and myocardial regeneration

机译:胶原蛋白生物材料治疗心肌梗死:心脏组织工程和心肌再生的更新

获取原文
获取原文并翻译 | 示例
           

摘要

Myocardial infarction (MI) remains one of the leading cause of mortality over the world. However, current treatments are more palliative than curative, which only stall the progression of the disease, but not reverse the disease. While stem cells or bioactive molecules therapy is promising, the limited survival and engraftment of bioactive agent due to a hostile environment is a bottleneck for MI treatment. In order to maximize the utility of stem cells and bioactive molecules for myocardial repair and regeneration, various types of biomaterials have been developed. Among them, collagen-based biomaterial is widely utilized for cardiac tissue engineering and regeneration due to its optimal physical and chemical properties. In this review, we summarize the properties of collagen-based biomaterial. Then, we discuss collagen-based biomaterial currently being applied to treat MI alone, or together with stem cells and/or bioactive molecules. Finally, the delivery system of collagen-based biomaterial will also be discussed.
机译:心肌梗塞(MI)仍然是世界上死亡的主要原因之一。然而,目前的治疗比治疗方法更加姑息,这只陷入疾病的进展,但不逆转疾病。虽然干细胞或生物活性分子治疗是有前途的,但由于敌对环境引起的生物活性剂的有限存活和植入是MI治疗的瓶颈。为了最大化干细胞和生物活性分子用于心肌修复和再生的效用,已经开发了各种类型的生物材料。其中,由于其最佳物理和化学性质,基于胶原基的生物材料广泛用于心脏组织工程和再生。在本文中,我们总结了基于胶原基的生物材料的性质。然后,我们讨论目前施用基于胶原的生物材料,以单独治疗MI,或与干细胞和/或生物活性分子一起治疗MI。最后,还将讨论基于胶原基的生物材料的递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号